KR20130036185A - 감염 치료 또는 예방 - Google Patents

감염 치료 또는 예방 Download PDF

Info

Publication number
KR20130036185A
KR20130036185A KR1020127022892A KR20127022892A KR20130036185A KR 20130036185 A KR20130036185 A KR 20130036185A KR 1020127022892 A KR1020127022892 A KR 1020127022892A KR 20127022892 A KR20127022892 A KR 20127022892A KR 20130036185 A KR20130036185 A KR 20130036185A
Authority
KR
South Korea
Prior art keywords
oral
gingivalis
subject
peptide
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127022892A
Other languages
English (en)
Korean (ko)
Inventor
에릭 찰스 레이놀즈
Original Assignee
오럴 헬스 오스트레일리아 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010900846A external-priority patent/AU2010900846A0/en
Application filed by 오럴 헬스 오스트레일리아 피티와이 엘티디 filed Critical 오럴 헬스 오스트레일리아 피티와이 엘티디
Publication of KR20130036185A publication Critical patent/KR20130036185A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127022892A 2010-02-26 2011-02-25 감염 치료 또는 예방 Ceased KR20130036185A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010900846A AU2010900846A0 (en) 2010-02-26 Treatment or prevention of infection
AU2010900846 2010-02-26
PCT/AU2011/000206 WO2011103633A1 (en) 2010-02-26 2011-02-25 Treatment or prevention of infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026249A Division KR20170109685A (ko) 2010-02-26 2011-02-25 감염 치료 또는 예방

Publications (1)

Publication Number Publication Date
KR20130036185A true KR20130036185A (ko) 2013-04-11

Family

ID=44506081

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127022892A Ceased KR20130036185A (ko) 2010-02-26 2011-02-25 감염 치료 또는 예방
KR1020177026249A Ceased KR20170109685A (ko) 2010-02-26 2011-02-25 감염 치료 또는 예방

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177026249A Ceased KR20170109685A (ko) 2010-02-26 2011-02-25 감염 치료 또는 예방

Country Status (17)

Country Link
US (1) US9125853B2 (enExample)
EP (2) EP2538970A4 (enExample)
JP (1) JP5977677B2 (enExample)
KR (2) KR20130036185A (enExample)
CN (2) CN102883744A (enExample)
AU (1) AU2011220335B2 (enExample)
BR (1) BR112012021383A2 (enExample)
CA (1) CA2790219C (enExample)
HK (1) HK1248535A1 (enExample)
MX (1) MX342832B (enExample)
MY (1) MY162557A (enExample)
NZ (1) NZ601890A (enExample)
RU (1) RU2617399C2 (enExample)
SG (2) SG183376A1 (enExample)
TW (1) TWI583392B (enExample)
WO (1) WO2011103633A1 (enExample)
ZA (1) ZA201206204B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587113B1 (ko) * 2014-10-29 2016-01-20 경북대학교 산학협력단 치주염 유발 장알균(Enterococcus faecalis)을 특이적으로 사멸시키는 신규한 박테리오파지

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
CN107266582B (zh) * 2008-08-29 2021-09-10 口腔健康澳洲私人有限公司 牙龈卟啉单胞菌感染的预防、治疗和诊断
US20110104179A1 (en) * 2009-06-19 2011-05-05 Oral Health Australia Pty Ltd Protease inhibitory peptides
WO2016061264A1 (en) * 2014-10-14 2016-04-21 The Forsyth Institute Conjugates for delivery to mitochondria
US10925951B2 (en) 2015-12-15 2021-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccination against diabetes, obesity and complications thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
MX2021011093A (es) 2019-03-13 2021-12-10 Univ Melbourne Composiciones y metodos para promover la mineralizacion.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
WO1993014779A1 (en) 1992-01-30 1993-08-05 Corvas International, Inc. Trypsin inhibitors
JPH0797395A (ja) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
AUPN627595A0 (en) 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
AUPP893999A0 (en) 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
AUPQ485999A0 (en) 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
GB2370838A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex
AU2003247754A1 (en) 2002-06-26 2004-01-19 Entremed, Inc Compositions and methods comprising protein activated receptor antagonists
JPWO2004083425A1 (ja) 2003-03-17 2006-06-22 麒麟麦酒株式会社 歯周病治療剤
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
AU2004266213A1 (en) * 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
GB0411150D0 (en) * 2004-05-19 2004-06-23 Queen Mary & Westfield College Vaccine
WO2006023844A2 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
EP1799705A4 (en) 2004-09-23 2008-11-05 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
US20100092471A1 (en) 2006-06-27 2010-04-15 Oral Health Australia Pty Ltd Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease
ES2714008T3 (es) 2007-07-12 2019-05-24 Oral Health Australia Pty Ltd Tratamiento de biopelícula
RU2366378C1 (ru) * 2008-04-07 2009-09-10 Сергей Владимирович Сирак Способ костной пластики при непосредственной дентальной имплантации
BR112012002429A2 (pt) * 2009-08-02 2016-11-08 Sanofi Pasteur Ltd polipeptídeos de porphyromonas gingivalis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587113B1 (ko) * 2014-10-29 2016-01-20 경북대학교 산학협력단 치주염 유발 장알균(Enterococcus faecalis)을 특이적으로 사멸시키는 신규한 박테리오파지

Also Published As

Publication number Publication date
US20130129768A1 (en) 2013-05-23
KR20170109685A (ko) 2017-09-29
CN102883744A (zh) 2013-01-16
EP2538970A4 (en) 2013-12-18
AU2011220335A1 (en) 2012-09-06
NZ601890A (en) 2015-01-30
JP2013520448A (ja) 2013-06-06
TW201138813A (en) 2011-11-16
US9125853B2 (en) 2015-09-08
SG10201500976XA (en) 2015-04-29
BR112012021383A2 (pt) 2017-07-25
MX2012009730A (es) 2013-02-07
AU2011220335B2 (en) 2015-04-02
CN104689308B (zh) 2020-10-20
RU2617399C2 (ru) 2017-04-24
CN104689308A (zh) 2015-06-10
HK1248535A1 (en) 2018-10-19
JP5977677B2 (ja) 2016-08-24
RU2012136724A (ru) 2014-04-10
TWI583392B (zh) 2017-05-21
EP2538970A1 (en) 2013-01-02
ZA201206204B (en) 2013-05-29
MY162557A (en) 2017-06-15
CA2790219C (en) 2020-06-30
WO2011103633A1 (en) 2011-09-01
SG183376A1 (en) 2012-09-27
EP3260135A1 (en) 2017-12-27
CA2790219A1 (en) 2011-09-01
MX342832B (es) 2016-10-14

Similar Documents

Publication Publication Date Title
US11572391B2 (en) Antibodies for prevention, treatment and diagnosis of P. gingivalis infection
HK1248535A1 (en) Treatment or prevention of infection
AU2011220335A2 (en) Treatment or prevention of infection
HK1157357A (en) Prevention, treatment and diagnosis of p.gingivalis infection
AU2013203249A1 (en) Prevention, treatment and diagnosis of P.gingivalis infection

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120831

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160225

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20160225

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

AMND Amendment
A302 Request for accelerated examination
AMND Amendment
PA0302 Request for accelerated examination

Patent event date: 20160422

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160523

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170221

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160523

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170221

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20161223

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160422

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160408

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160225

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170621

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170523

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170221

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161223

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160523

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160422

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160408

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160225

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170918